Top Page
CASI Pharmaceuticals
(NASDAQ:CASI)
CASI Pharmaceuticals (CASI) vs. SPDR S&P 500 ETF (SPY)
CASI Pharmaceuticals Business Overview & Revenue Model
CASI Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.85M | 28.54M | 33.88M | 43.11M | 30.17M | 15.14M |
| Gross Profit | 9.61M | 11.15M | 20.05M | 27.28M | 17.61M | 5.63M |
| EBITDA | -41.37M | -34.87M | -21.54M | -24.07M | -33.40M | -31.35M |
| Net Income | -49.38M | -39.26M | -26.94M | -41.01M | -36.65M | -48.29M |
Balance Sheet | ||||||
| Total Assets | 24.46M | 53.67M | 75.27M | 96.23M | 138.30M | 127.73M |
| Cash, Cash Equivalents and Short-Term Investments | 4.68M | 16.09M | 30.77M | 51.34M | 48.57M | 66.37M |
| Total Debt | 18.86M | 22.14M | 21.24M | 1.34M | 4.33M | 3.20M |
| Total Liabilities | 53.05M | 51.82M | 51.10M | 29.30M | 30.34M | 24.16M |
| Stockholders Equity | -28.59M | 1.85M | 24.16M | 44.57M | 84.50M | 81.54M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -29.46M | -22.21M | -26.70M | -42.34M | -45.21M |
| Operating Cash Flow | 0.00 | -29.22M | -19.97M | -21.09M | -26.84M | -25.89M |
| Investing Cash Flow | 0.00 | 11.24M | -9.67M | 31.16M | -20.69M | -20.72M |
| Financing Cash Flow | 0.00 | 15.43M | -907.00K | -3.27M | 29.64M | 47.15M |
CASI Pharmaceuticals Technical Analysis
CASI Pharmaceuticals Risk Analysis
CASI Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $15.80M | -0.31 | ― | ― | 26.20% | -42.26% | |
46 Neutral | $4.85M | -0.06 | -377.44% | ― | 8.52% | 79.51% | |
45 Neutral | $11.61M | -0.24 | ― | ― | 13.56% | 52.92% | |
45 Neutral | $13.21M | -0.07 | ― | ― | ― | 79.31% | |
43 Neutral | $9.39M | -1.52 | -79.47% | ― | -99.97% | 35.59% |
CASI Pharmaceuticals Corporate Events
On January 22, 2026, CASI Pharmaceuticals reported that China’s National Medical Products Administration formally rejected its May 2025 application to renew the Import Drug Registration License for FOLOTYN®, following earlier correspondence from the Chinese Center for Drug Evaluation indicating the renewal would not be granted. After the prior license expired, CASI had already halted sales of FOLOTYN® in China in line with regulatory requirements, underscoring a further setback for its commercial oncology portfolio in the country amid ongoing disputes and legal proceedings over other pipeline assets, including EVOMELA® and CNCT-19.
The most recent analyst rating on (CASI) stock is a Hold with a $0.97 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
On January 13, 2026, CASI Pharmaceuticals announced it had closed the second tranche of its previously arranged US$20 million convertible note financing with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He, issuing a new US$5 million convertible note. The note carries a 12% annual interest rate, matures in 36 months, and may be converted into ordinary shares either at the company’s option at maturity or at the investor’s option after 90 days, with the conversion price set to a five-day volume-weighted average and capped between US$1 and US$2 per share, a structure that provides CASI with near-term funding while potentially diluting existing shareholders depending on future share price performance.
The most recent analyst rating on (CASI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
On December 30, 2025, CASI Pharmaceuticals announced that it had closed the first tranche of a US$20 million convertible note financing, issuing a US$5 million note to ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He. The three-year note carries a 12% annual interest rate and is convertible into CASI ordinary shares at a price based on the volume-weighted average trading price over a five-day period, subject to a cap of US$2 and a floor of US$1 per share, with conversion rights available to CASI at maturity and to the investor from the 91st day after issuance, providing the company with near-term funding flexibility while potentially diluting existing shareholders over time.
The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
On December 23, 2025, CASI Pharmaceuticals announced that a Nasdaq Hearings Panel granted the company an extension to remain listed on the Nasdaq Capital Market, provided it regains compliance with the Market Value of Listed Securities requirement by February 17, 2026. The extension, which follows an initial deficiency notice issued on May 5, 2025 and a prior grace period through November 3, 2025, temporarily halts any suspension of CASI’s securities while the company works to restore its market value above the $35 million threshold. The Panel’s decision took into account CASI’s recent strategic moves, including leadership changes, a renewed focus on executing development of CID-103, a convertible note financing, ongoing funding initiatives, and a planned divestiture of its China assets, signaling both operational restructuring and continued pressure to stabilize its financial and market position for investors and other stakeholders.
The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
On December 11, 2025, CASI Pharmaceuticals announced a $20 million convertible note financing agreement with ETP Global III Fund LP to support a Phase 1 study in China for renal allograft antibody-mediated rejection (AMR). This investment, structured in tranches, will also aid in developing a stable, high concentration protein solution for subcutaneous formulation, potentially enhancing CASI’s market position in biopharmaceuticals. The financing reflects strategic growth efforts, although it involves risks such as market volatility and operational challenges.
The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
On November 19, 2025, CASI Pharmaceuticals announced a significant change in its board governance with the appointment of James Huang as the Non-Executive Chairman of the Board, effective November 17, 2025. This move is part of a strategic effort to enhance governance and drive growth, as Dr. Wei-Wu He steps down from the Executive Chairman role but remains on the board. The appointment reflects confidence in Huang’s vision and leadership as the company advances its CID-103 development, particularly in addressing organ transplant rejection. This governance change is expected to align with shareholder interests and sustain the company’s long-term success.
The most recent analyst rating on (CASI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
On November 14, 2025, CASI Pharmaceuticals announced its third-quarter 2025 business and financial results, highlighting ongoing advancements in its CID-103 clinical program. The company is preparing for a Phase 1 study in the U.S. for renal allograft antibody-mediated rejection (AMR) and is conducting a Phase 1 study for immune thrombocytopenia (ITP). Financially, CASI reported a 60% decrease in revenue to $3.1 million compared to the previous year, primarily due to changes in the distribution agreement for EVOMELA®. The company also faced a net loss increase to $10.9 million and received a Nasdaq delisting determination due to non-compliance with market value requirements, which it is appealing.
The most recent analyst rating on (CASI) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
CASI Pharmaceuticals announced that it received a delisting determination from Nasdaq due to its market value of listed securities falling below the minimum requirement for an extended period. The company has appealed the decision and is working on a compliance plan to maintain its Nasdaq listing, which is crucial for its operations and investor confidence.
The most recent analyst rating on (CASI) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.